TARGETED MOLECULAR DIAGNOSTICS has a total of 21 patent applications. Its first patent ever was published in 2005. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are BOUGUELERET LYDIE, MASSACHUSETTS HEALTH RES and KINCH MICHAEL S.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 4 | |
#3 | China | 3 | |
#4 | Republic of Korea | 3 | |
#5 | Canada | 2 | |
#6 | EPO (European Patent Office) | 2 | |
#7 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Bacus Sarah S | 15 |
#2 | Hill Jason E | 9 |
#3 | Kochupurakkal Bose S | 5 |
#4 | Yarden Yosef | 5 |
#5 | Bacus Sarah | 3 |
#6 | Hill Jason | 2 |
#7 | Yarden Josef | 1 |
#8 | Yosef Yarden | 1 |
Publication | Filing date | Title |
---|---|---|
WO2008109332A2 | Methods and compositions for determining the efficacy of breast cancer therapeutics | |
WO2008016730A2 | Compositions and methods for reducing cellular fat | |
CN101611150A | Bivalent erbb ligand binding molecules and preparation thereof and using method | |
US2006127928A1 | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |